A Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-Resistant Serratia marcescens Biofilms

This study demonstrates that a triple-modality therapy combining bacteriophages, sub-minimal inhibitory concentration antibiotics, and antimicrobial peptides effectively eradicates multidrug-resistant *Serratia marcescens* biofilms by simultaneously targeting multiple cellular mechanisms, offering a promising solution for device-associated infections.

The Gist

The Problem: The "Fortress" Bacteria

Imagine a very stubborn, invisible burglar named Serratia marcescens. This bacterium loves to hang out in hospitals, especially in places like sinks, ventilators, and IV tubes.

The problem is that this burglar doesn't just hide; it builds a fortress. It creates a sticky, slimy shield called a biofilm. Think of this biofilm like a medieval castle with thick stone walls. Inside this castle, the bacteria are safe. They are also "multidrug-resistant" (MDR), meaning they have learned to ignore almost all the standard weapons (antibiotics) doctors usually use to fight them.

When doctors try to wash these fortresses away with standard disinfectants or antibiotics, the drugs often bounce off the walls or get neutralized before they can kill the bacteria inside. This leads to dangerous infections that are very hard to cure.

The Experiment: Trying Different Weapons

The scientists in this paper wanted to find a way to smash this fortress. They tested three different types of "weapons" on their own and then tried combining them:

1. The Antibiotics (The Sledgehammers): These are standard drugs that try to break the bacteria's cell walls or stop them from making proteins.
   • Result: Alone, they were like trying to break a castle wall with a plastic hammer. They could chip away a little bit, but they couldn't destroy the whole fortress.
2. The Bacteriophages (The Specialized Snipers): These are viruses that only eat bacteria. They are like a sniper who knows exactly where the castle guard is hiding. They sneak in and hijack the bacteria from the inside to make them explode.
   • Result: They were better than the sledgehammers, but the bacteria were still tough. The snipers could take out some guards, but the fortress remained standing.
3. The Antimicrobial Peptides (The Acid Spray): These are tiny, naturally occurring molecules that act like a corrosive acid. They punch holes in the bacteria's outer skin (membrane).
   • Result: Alone, they were okay, but not enough to wipe out the whole army.

The Breakthrough: The "Triple-Modality" Team-Up

The scientists realized that fighting a fortress with just one type of weapon wasn't working. So, they decided to send in a special forces team using all three weapons at the exact same time. This is called the BAP therapy (Bacteriophage + Antibiotic + Peptide).

Here is how the team worked together, using a creative analogy:

• Step 1: The Acid Spray (Peptides): First, the peptides act like a corrosive spray that weakens the castle's outer walls and punches holes in the gates. The bacteria's defenses are compromised.
• Step 2: The Sledgehammers (Antibiotics): Because the walls are now weak and full of holes, the antibiotics can finally get inside. They start smashing the machinery inside the castle (stopping the bacteria from making food or copying their DNA).
• Step 3: The Snipers (Phages): With the bacteria confused, injured, and their defenses down, the phages (snipers) move in. They easily find the bacteria, hijack them, and cause them to burst open.

The Result: Total Decolonization

When they used this "Triple-Modality" team, the results were incredible.

• The Fortress Crumbled: They didn't just weaken the biofilm; they completely destroyed it.
• The Burglars Vanished: They killed 99.99% of the bacteria, including the super-tough ones that usually survive everything.
• No Regrowth: The bacteria didn't come back. The "castle" was leveled.
• Safe for Humans: They tested this mixture on human lung cells, and it didn't hurt them at all. It was a "smart bomb" that only hit the bacteria.

Why This Matters

This study is a game-changer because it shows that when bacteria build a fortress and learn to resist our best weapons, we don't need a bigger hammer. We need a coordinated team that attacks from multiple angles at once.

By combining a virus, a drug, and a peptide, the scientists found a way to erase these dangerous, drug-resistant infections that have been plaguing hospitals for years. It's like realizing that to defeat a dragon, you don't just need a sword; you need a sword, a shield, and a fire extinguisher working together perfectly.

Technical Summary

1. Problem Statement

• Pathogen: Serratia marcescens is a Gram-negative opportunistic pathogen responsible for severe hospital-acquired infections, particularly in immunocompromised, neonatal, and geriatric patients.
• Key Challenges:
  • Biofilm Formation: The bacterium forms robust biofilms on medical devices (catheters, ventilators) and hospital surfaces, which protect it from host immune responses and standard disinfectants.
  • Antimicrobial Resistance (AMR): S. marcescens exhibits intrinsic resistance (efflux pumps, reduced permeability, AmpC $\beta$-lactamases) and acquired resistance (horizontal gene transfer, mutations in gyrA/gyrB, plasmid-mediated resistance like blaKPC).
  • Therapeutic Failure: Standard monotherapies and even high-dose antibiotic lock therapies often fail to eradicate mature biofilms due to poor penetration of the extracellular matrix and the high tolerance of biofilm-embedded bacteria. Current disinfectants (bleach, QACs) are often ineffective against mature biofilms in organic-rich environments.

2. Methodology

The study utilized an in vitro model to evaluate a multi-modal therapeutic approach against 14 multidrug-resistant (MDR) S. marcescens isolates (including CDC clinical isolates and environmental strains).

• Strains: 14 isolates were categorized into "MDR Base" (high MIC for $\ge$3 antibiotics) and "MDR Plus" (broader resistance profiles, including blaKPC carriers).
• Therapeutic Agents:
  • Antibiotics: A sub-MIC (Minimum Inhibitory Concentration) cocktail targeting multiple pathways: Penicillin-Streptomycin (cell wall/protein synthesis), Ciprofloxacin (DNA gyrase/topoisomerase), and Kanamycin (30S ribosomal subunit).
  • Bacteriophages: Two lytic phages ($\phi$JCVI_Sm1 and $\phi$JCVI_Sm2) isolated from municipal wastewater.
  • Antimicrobial Peptides (AMPs): A cocktail of four peptides derived from Lentilactobacillus hilgardii, known to disrupt membrane integrity.
• Experimental Models:
  • Planktonic Growth: Measured via OD600 to assess bacterial density.
  • Biofilm Assays: Static biofilms grown for 48 hours, treated, and quantified via Crystal Violet staining (OD495).
  • Viability Assays: Colony Forming Units (CFU) counts in supernatant and scraped biofilm fractions.
  • Microscopy: Live/Dead fluorescent staining (SYTO 9/Propidium Iodide) and confocal microscopy to visualize biofilm architecture and cell viability.
  • Toxicity: Lactate Dehydrogenase (LDH) release assay on human alveolar epithelial cells (A549) to assess cytotoxicity.

3. Key Contributions

• Development of a Triple-Modality Therapy (BAP): The study proposes and validates a "BAP" regimen combining Bacteriophages, Antibiotics, and Peptides.
• Mechanistic Synergy: The therapy simultaneously targets four distinct bacterial defense mechanisms:
  1. Cell wall synthesis inhibition (Penicillin-Streptomycin).
  2. Protein translation inhibition (Kanamycin).
  3. DNA replication inhibition (Ciprofloxacin).
  4. Membrane integrity disruption (AMPs).
  5. Host machinery hijacking and lysis (Phages).
• Strain Stratification: The authors identified distinct resistance clusters ("MDR Base" vs. "MDR Plus") and demonstrated that while phage-antibiotic combinations work on "Base" strains, the addition of AMPs is required to overcome the tolerance of "Plus" strains.

4. Key Results

• Single Agent Limitations:
  • Single antibiotics showed variable efficacy against planktonic cells but were significantly less effective against mature biofilms.
  • Phage therapy alone reduced biofilm biomass but did not achieve complete decolonization.
• Synergy of Phage + Antibiotics:
  • Combining sub-MIC antibiotics with phages (MOI 0.1) resulted in an 88% reduction in biofilm biomass, significantly outperforming antibiotics alone (63%) or phages alone.
  • However, this combination failed to eradicate "MDR Plus" strains (e.g., AR-0517), which showed tolerance to the phage-antibiotic cocktail.
• Efficacy of Triple-Modality (BAP):
  • Complete Eradication: The addition of AMPs to the phage-antibiotic cocktail (BAP) eradicated 99.99% of MDR isolates, including the highly resistant "MDR Plus" strains.
  • Biofilm Disruption: BAP treatment reduced biofilm biomass by 97.8% in the most resistant strain (AR-0517), surpassing all other permutations (Antibiotics+Peptides: 76.4%; Phage+Peptides: 16.2%).
  • Viability: CFU counts confirmed near-total bacterial clearance (>99.99% reduction) in both planktonic and biofilm fractions.
  • Microscopy: Live/Dead staining confirmed that biomass reduction correlated with bacterial killing, not just matrix disruption.
• Safety: The BAP cocktail showed no observable cytotoxicity to human A549 lung epithelial cells after 12 or 24 hours of exposure.

5. Significance

• Overcoming Resistance: This study demonstrates that a multi-target approach can bypass the complex resistance mechanisms (efflux pumps, biofilm matrix, genetic mutations) that render standard therapies ineffective against S. marcescens.
• Clinical Relevance: The BAP strategy offers a promising solution for treating device-associated infections (e.g., catheter-related bloodstream infections) and decolonizing hospital environments where S. marcescens biofilms persist.
• Future Directions: The findings support the translation of multi-tier antimicrobial therapies into in vivo models and highlight the potential of combining phage therapy with sub-MIC antibiotics and AMPs as a standard protocol for managing MDR Gram-negative pathogens.

In conclusion, the paper establishes that while single or dual therapies struggle against MDR S. marcescens biofilms, a synergistic triple-modality approach targeting cell wall, protein synthesis, DNA replication, and membrane integrity achieves near-complete decolonization without harming mammalian cells.